Literature DB >> 20200397

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

David Cunningham, Alicia F C Okines, Sue Ashley.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20200397     DOI: 10.1056/NEJMc0911925

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  54 in total

1.  Clinical use of trastuzumab combined with different chemotherapy regimens in multi-line treatment of advanced human epidermal growth factor receptor 2-positive gastric cancer: A case report.

Authors:  Zhe-Ling Chen; Andi Zhao; Pan Li; Mi Zhang; Jiao Yang; Lingxiao Zhang; Xiaoai Zhao; Jin Yang; Le Wang
Journal:  Oncol Lett       Date:  2018-07-25       Impact factor: 2.967

2.  Outcomes in gastric and junctional cancer using neoadjuvant and adjuvant chemotherapy (epirubicin, oxaliplatin, and capecitabine) and radical surgery.

Authors:  A M Mongan; R Kalachand; S King; N J O'Farrell; D Power; N Ravi; C Muldoon; K O'Byrne; J V Reynolds
Journal:  Ir J Med Sci       Date:  2014-05-31       Impact factor: 1.568

3.  The prognostic impact of EGFR, ErbB2 and MET gene amplification in human gastric carcinomas as measured by quantitative Real-Time PCR.

Authors:  Ghasem Janbabai; Ziaeddin Oladi; Touraj Farazmandfar; Tarang Taghvaei; Farshad Naghshvar
Journal:  J Cancer Res Clin Oncol       Date:  2015-03-29       Impact factor: 4.553

Review 4.  Adjuvant therapy for gastric cancer: what have we learned since INT0116?

Authors:  Alexandre A Jácome; Ajith K Sankarankutty; José Sebastião dos Santos
Journal:  World J Gastroenterol       Date:  2015-04-07       Impact factor: 5.742

5.  Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections.

Authors:  Nobuyuki Takemura; Akio Saiura; Rintaro Koga; Junichi Arita; Ryuji Yoshioka; Yoshihiro Ono; Naoki Hiki; Takeshi Sano; Junji Yamamoto; Norihiro Kokudo; Toshiharu Yamaguchi
Journal:  Langenbecks Arch Surg       Date:  2012-05-22       Impact factor: 3.445

6.  Ramucirumab for the treatment of gastroesophageal cancers.

Authors:  Y Shimodaira; E Elimova; R Wadhwa; H Shiozaki; N Charalampakis; V Planjery; J E Rogers; S Song; J A Ajani
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-25       Impact factor: 0.694

7.  High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study.

Authors:  Koji Komeda; Michihiro Hayashi; Shoji Kubo; Hiroaki Nagano; Takuya Nakai; Masaki Kaibori; Hiroshi Wada; Shigekazu Takemura; Masahiko Kinoshita; Chikato Koga; Masataka Matsumoto; Tatsuma Sakaguchi; Yoshihiro Inoue; Fumitoshi Hirokawa; A-Hon Kwon; Kazuhisa Uchiyama
Journal:  World J Surg       Date:  2014-10       Impact factor: 3.352

8.  Trimodality therapy for stage II-III carcinoma of the esophagus: a dose-ranging study of concurrent capecitabine, docetaxel, and thoracic radiotherapy.

Authors:  Matthew D Wood; Bassem I Zaki; Stuart R Gordon; John E Sutton; Mikhail Lisovsky; Jiang Gui; Jeffrey A Bubis; Konstantin H Dragnev; James R Rigas
Journal:  J Thorac Oncol       Date:  2013-04       Impact factor: 15.609

9.  Change of HER2 status in metastatic esophageal adenocarcinoma: heterogeneity of the disease? Case report and review of literature.

Authors:  Jiaxin Niu; Jeffrey Weber; Deborah Gelbspan
Journal:  J Gastrointest Oncol       Date:  2012-12

10.  Repeat hepatectomy for recurrent liver metastasis from gastric carcinoma.

Authors:  Nobuyuki Takemura; Akio Saiura; Rintaro Koga; Ryuji Yoshioka; Junji Yamamoto; Norihiro Kokudo
Journal:  World J Surg       Date:  2013-11       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.